// December 18, 2025
Extractables and Leachables Testing: Driving Global Standards Through Dialogue...
Key points:
Supply Chain
// January 21, 2026
Protective Purchasing: A Hidden Amplifier of Drug Shortages...
Discover how drug shortage announcements drive protective purchasing, impacting supply, demand, and patient access across the U.S. healthcare system.
// January 08, 2026
Global manufacturing capacity for active pharmaceutical ingredients remains concentra...
The globalization of the medicines supply chain has helped to increase access to quality medicines at a lower cost. At the same time, the supply chain has grown longer, more complex, and fragmented, leading to a lack of visibility and increase in the risk to its resilience. In many instances, globalization has also led to the concentration of production in a few geographies. Insights from USP’s Medicine Supply Map demonstrate that geographic concentration of pharmaceutical manufacturing anywhere in the world – including within the United States – increases the risk for drug shortages.
// December 11, 2025
Different medicines, same chokepoints: Key starting materials concentrate supply chai...
USP’s ongoing series on geographic concentration in U.S.
// December 04, 2025
Reflections from SCoMRA VII: Unlocking Africa’s pharmaceutical future through Strong ...
Discover insights from SCoMRA VII on Africa’s pharmaceutical future, regulatory harmonization, and USP initiatives driving access to quality medicines.
// July 28, 2025
India and the EU dominate API manufacturing for the most-used ATC-3 therapeutic class...
This blog continues our exploration of global pharmaceutical supply chain vulnerabilities, specifically the geographic concentration of active pharmaceutical ingredient (API) manufacturing.
// April 17, 2025
Over half of the active pharmaceutical ingredients (API) for prescription medicines i...
Geographic concentration of active pharmaceutical ingredient (API) manufacturing volume shows that US generics come mainly from India, while Europe leads for branded drugs. US tariffs often apply based on where the API was made.
// February 19, 2025
India and the United States manufacture most finished medicines for the U.S. market...
Natural disasters, trade wars and pandemics are just some of the disruptions that the U.S. pharmaceutical supply chain has faced in recent years. Identifying where drug products are made is a first step in characterizing the risk associated with these events. Learn more.
Show 11 More